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Differential reprogramming 
of breast cancer subtypes 
in 3D cultures and implications 
for sensitivity to targeted therapy
Esmee Koedoot1*, Liesanne Wolters1, Marcel Smid2, Peter Stoilov3, Gerhard A. Burger1, 
Bram Herpers4, Kuan Yan4, Leo S. Price4, John W. M. Martens2, Sylvia E. Le Dévédec1 & 
Bob van de Water1 
Screening for effective candidate drugs for breast cancer has shifted from two-dimensional (2D) 
to three-dimensional (3D) cultures. Here we systematically compared the transcriptomes of these 
different culture conditions by RNAseq of 14 BC cell lines cultured in both 2D and 3D conditions. All 
3D BC cell cultures demonstrated increased mitochondrial metabolism and downregulated cell cycle 
programs. Luminal BC cells in 3D demonstrated overall limited reprogramming. 3D basal B BC cells 
showed increased expression of extracellular matrix (ECM) interaction genes, which coincides with an 
invasive phenotype not observed in other BC cells. Genes downregulated in 3D were associated with 
metastatic disease progression in BC patients, including cyclin dependent kinases and aurora kinases. 
Furthermore, the overall correlation of the cell line transcriptome to the BC patient transcriptome was 
increased in 3D cultures for all TNBC cell lines. To define the most optimal culture conditions to study 
the oncogenic pathway of interest, an open source bioinformatics strategy was established.
Breast cancer is the most prevalent cancer and the second leading cause of cancer death in women with an 
estimated 40,610 deaths in the United States in  20171. Based on levels of the estrogen, progesterone and HER2 
receptors, breast cancer can be divided in different subtypes. The triple-negative subtype (TNBC) lacking the 
expression of these three hormone receptors accounts for 15–20% of all  tumors2 and is the most aggressive sub-
type, often leading to  metastases3,4. Despite the efforts, there is still no targeted therapy for TNBC  available5. A 
major reason for this lack in clinical translation may be the use of two-dimensional in vitro experiments that do 
poorly represent the three-dimensional (3D) tissue physiology observed in human cancer patients. To increase 
translation from in vitro findings to a clinical setting, different 3D culture systems are now explored, such as 
organoid cultures, patient-derived xenograft models, reprogrammed stem cell like models, tumor-on-a-chip 
and 3D cultures of immortalized breast cancer cell  lines6. While the majority of breast cancer drug screening 
studies in the last decade have still been performed in  2D7–12, there is an increasing number of drug screens per-
formed in more complex models such as patient-derived  organoids13,14, tumor-on-a-chip15 and patient-derived 
 xenograft16 models. Although these complex models better represent human physiology and should increase 
clinical  translation17–19, drawbacks of these models include reduced  reproducibility17,20,21, increasing costs, incon-
venient maintenance, difficulties in expanding them and generating genetic modifications, making these models 
less suitable for high-throughput  screening22. Next to the already widely studied phenotypic changes between 
different culturing  models16,23 and phenotypic classification of different tumor  subtypes6, transcriptomic and 
proteomic analyses can contribute to the understanding of the differences between established in vitro models 
and help to determine the most suitable model in terms of both clinical translation, costs and efficiency.
Here, we performed RNA-sequencing of 14 breast cancer cell lines cultured on a 2D plastic substrate as well 
as in a 3D matrigel-collagen environment. In this 3D model, cells spontaneously form spheroid-like structures 
exhibiting cell–cell as well as cell–extracellular matrix interactions, thereby changing their cell polarity and 
shape. We unraveled the transcriptomic differences linked to the invasive phenotype of basal B (or claudin-low) 
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TNBC compared to basal A and luminal breast cancer and uncovered a spectrum of genes higher expressed in 
2D cultures that were related to metastatic progression in breast cancer patients. Since the transcriptomic cor-
relation of in vitro cultured cell models to patient tumor tissue was highly subtype and pathway dependent, we 
established a bioinformatics tool that can be used in future studies to select the most suitable cell type and culture 
conditions for the pathway of interest. Altogether, this study unraveled the transcriptomic variance between dif-
ferent breast cancer in vitro models and provides an important database that can contribute to selection of the 
most effective and relevant drug candidates for the treatment of TNBC.
Results
mRNA profiling of breast cancer cells cultured in 3D revealed downregulation of cell 
cycle-related genes and upregulation of mitochondrial genes. To understand how cell culture sys-
tems affect the transcriptome of breast cancer (BC) cells, we performed RNA sequencing of 52 human breast 
cancer cell lines cultured on 2D tissue culture plastic and 14 cell lines cultured in a 3D matrigel-collagen envi-
ronment (Fig. 1A, Suppl. Table 1). The selection of the 14 cell lines was based on previously defined subtype 
 classifications24–28 with selected cell lines representing the different BC subtypes (luminal, basal A and basal B 
(often named claudin-low)). These cell line subtypes were validated in our RNA sequencing dataset; hierarchical 
clustering based on RNA expression of previously published luminal and basal markers clearly separated the 
different subtypes (Fig. 1B and Suppl. Fig. 1, Suppl. Table 2)24,29. Moreover, cell lines could also be assigned to 
these subtypes based on whole transcriptomic differences (Fig. 1C). Three cell lines (SUM149PT, SUM225CWN 
and HCC1500) did not cluster with their assigned subtype (Fig. 1B), which was in agreement with the ambigu-
ous subtype classification described in the literature (Suppl. Table 3)24–28. To visualize the global transcriptomic 
differences between 2 and 3D culturing systems, we created a T-sne plot using RNA expression levels from the 
cell lines that were cultured both in 2D and 3D culture conditions (Fig. 1D). Cell lines separated consistently 
based on their subtype and, interestingly, the differences between cell lines were much larger than the differ-
ences between 2D/3D culture conditions; 2D and 3D samples of the same cell line clustered together (Fig. 1D, 
encircled). However, these 2D and 3D samples were still clearly separated, revealing significant changes in gene 
expression patterns between the different culture conditions. To investigate the altered pathways comparing 2D 
to 3D culturing conditions, we calculated the significantly differentially expressed genes (DEGs) pairing 2D and 
3D samples for every cell line, followed by over-representation analysis (Fig. 1E/F) and ranked gene set enrich-
ment analysis (GSEA) (Fig. 1G). In total, we identified 452 genes higher expressed in 2D and 1762 genes higher 
expressed in 3D (Suppl. Table 4). Over-represented and enriched pathways in 2D cultures include mainly cell 
cycle and cancer related pathways (Fig. 1E/G/H/I), while pathways related to oxidative phosphorylation and 
transcription were higher expressed in 3D systems.
3D culturing induced expression of extracellular matrix organization genes in Basal B cell 
lines. Previously, we showed that gene expression differences between 2 and 3D cultures can be subtype and 
cell line specific. Therefore, we now examined the DEGs for each cell line. On average, ~ 3000 genes were higher 
expressed in 2D per cell line (log2 fold change > 1) (Suppl. Fig. 2A), independent of cell line or subtype. Interest-
ingly, in 3D cultures the number of DEGs was higher in basal compared to luminal cell lines (~ 2000 vs. 4500; 
Fig. 2A and Suppl. Fig. 2B). This was confirmed by the number of significantly DEGs per subtype: for the lumi-
nal subtype ~ 200 genes were higher expressed in both 2D and 3D, while for the basal subtype also ~ 200 genes 
were higher expressed in 2D, but ~ 800 (basal A) and ~ 1100 (basal B) genes were upregulated in 3D (Fig. 2B). 
Furthermore, the majority of the DEGs for the basal subtypes were overlapping (Suppl. Fig. 2C). Interestingly, 
while in 2D cultures both basal A and basal B subtypes displayed an active migratory behavior (Suppl. Fig. 3), in 
3D cultures only basal B showed an invasive phenotype (Fig. 2C). Similar morphological differences were previ-
ously observed by us and others when cell lines were cultured on top of a 3D laminin-rich extracellular matrix 
composed of matrigel and bone marrow  extract30. In order to identify the underlying pathways that contribute 
to this differential invasive capacity, we performed an over-representation analysis for the subtype-specific DEGs 
in basal A and basal B cell lines (Fig. 2D/E, Suppl. Fig. 2D/E). Remarkably, pathways related to cell–matrix inter-
actions, extracellular matrix organization, collagen synthesis and integrin cell surface interactions were higher 
expressed in 2D for the basal A subtype (Fig. 2D), while higher expressed in 3D for the basal B subtype (Fig. 2E). 
Only a small subset of the extracellular matrix organization pathway was upregulated in 3D settings in basal B 
cell lines, while equally expressed or down-regulated in basal A cells (Fig. 2F). Interestingly, this subset includes 
the genes PLOD1, P3H3 and P3H4, which together form a complex that catalyzes hydroxylation of lysine resi-
dues in collagen chains and is required for proper collagen biosynthesis and  modification31 (Fig. 2G). Other 
interesting members identified in this clusters are genes involved in cell adhesion, such as ITGB1 (Fig. 2G) and 
genes involved in breakdown of the extracellular matrix such as TIMP2 (Fig. 2G).
Metastatic breast cancer genes are downregulated in 3D cultures. Our analysis of the differential 
mRNA profiles between 2 and 3D cultures provided us with new insights on the transcriptional reprogram-
ming related to basal cell line invasiveness in 3D cultures. Next, we wondered whether these newly identified 
DEGs would also play a role in breast cancer progression and metastasis formation in patients. Therefore, we 
examined the expression of DEGs in the different primary breast tumor subtypes using RNA sequencing data 
from 923 primary breast tumors (116 TNBC and 807 ER positive (of which 682 PR positive) tumors) derived 
from The Cancer Genome Atlas (TCGA). Since we observed clear differences in culture-specific gene expression 
changes for the different subtypes, we performed these analyses for the DEGs obtained from the paired analysis 
for all cell lines, basal A and basal B specific DEGs (Fig. 3A). Independent of the cell line subtype, DEGs higher 
expressed in 3D were higher expressed in the less aggressive ER positive subtype, while DEGs higher expressed 
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in 2D were higher expressed in the more aggressive TNBC subtype (Fig. 3B,C). To investigate if these DEGs 
are also associated with metastatic progression in breast cancer patients, the hazard ratios (HRs) for distant 
metastasis-free survival (DMFS) were examined using microarray data of 867 untreated lymph-node negative 
breast cancer patients (Fig. 3A). DEGs with a significant HR were selected and the distribution of these HRs was 
plotted (Fig. 3D). DEGs higher expressed in 3D showed slightly more DEGs of which high expression is nega-
tively related to metastatic progression in all subtypes (HR < 1). Interestingly, DEGs higher expressed in 2D were 
mainly positively related to metastatic progression (HR > 1) independent of the subtype. Examples of such DEGs 
down-regulated in 3D cultures and significantly related to metastatic progression were cyclin dependent kinases 
(CDKs), aurora kinases (Fig. 3E,F) and proteasomal factors (Suppl. Fig. 4A-B). Since dysregulation of cell cycle 
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Figure 1.  RNA sequencing of breast cancer cell lines cultured in 2D and 3D environments. (A) Experimental 
overview. RNA was isolated from cell lines cultured in 2D and 3D conditions (see Methods section for more 
details), upon which next generation sequencing was performed. Cell line specific Differentially Expressed 
Genes (DEGs) were selected based on log2 fold change > 1 or <  − 1. Subtype specific DEGs were determined 
using a paired cell line analysis and selected if the parametric p-value < 0.01. See “Methods” section for further 
details. (B) Hierarchical clustering (complete linkage, correlation) of log2 expression levels of previously defined 
basal and luminal  identifiers29 in 2D cultured cell lines. For every gene, expression levels were normalized to 
the median cell line expression. (C) T-sne of all cell lines cultured in 2D based on log2 normalized reads from 
all detected genes. Encircled cell lines were also cultured in 3D in this study. (D) T-sne of cell lines cultured in 
both 2D and 3D conditions based on log2 normalized reads from all detected genes. 2D and 3D conditions of 
the same cell line are encircled. (E) Top 10 over-represented pathways in DEGs higher expressed in 2D cultures. 
DEGs were determined using paired analysis for all cell lines, p < 0.01. (F) Top 10 over-represented pathways in 
DEGs higher expressed in 3D cultures. DEGs were determined using paired analysis for all cell lines, p < 0.01. 
(G) Top 10 enriched pathways higher expressed in 2D cultures using a ranked gene set enrichment analysis 
(GSEA). (H) and (I) Examples of GSEA of pathways enriched in 2D cultures. The enrichment score (ES) 
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is one of the hallmarks of  cancer32, CDKs and aurora kinases are attractive targets for new cancer  therapy33–36. 
Moreover, cancer cells might be more dependent on the proteasome for the elimination of abnormal proteins 
due to high proliferation rate and genetic  instability37,38. Altogether, DEGs higher expressed in 2D cultures were 
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Figure 2.  Subtype specific differences in 2D and 3D breast cancer cultures. (A) Density plot of log2 fold 
change in gene expression comparing 2D to 3D cultures of 14 cell lines (4 basal A, 4 basal B and 6 luminal). (B) 
Significantly DEG count for different subtypes based on paired analysis and p < 0.01. (C) Cellular morphology 
of basal A and basal B cell lines cultured in 3D. (D) Top 10 over-represented pathways in the high 2D DEGs in 
basal A cell lines. Migration and invasion related pathways are highlighted in red. DEGs were determined by 
paired analysis of basal A cell lines, p < 0.01. (E) Top 10 over-represented pathways in the high 3D DEGs in basal 
B cell lines. Migration and invasion related pathways are highlighted in red. DEGs were determined by paired 
analysis of basal B cell lines, p < 0.01. (F) Heatmap (complete linkage, Euclidean distance) of log2 fold change 
in expression of genes in the extracellular matrix organization pathway comparing 2D to 3D cultures. (G) Log2 
fold change of expression levels of genes in the extracellular matrix pathway comparing 2D to 3D cultures in 
basal A and basal B cell lines. Selected genes were higher expressed in 2D in the basal A cell lines, but higher 
expressed in 3D in the basal B cell lines. Log2 fold change was determined using a paired analysis per subtype.
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Figure 3.  Role of DEGs in breast cancer aggressiveness and metastasis formation. (A) Significantly DEGs 
comparing all cell lines, basal A cell lines or basal B cell lines were selected using a paired cell line analysis per 
subtype, p < 0.01. For these genes, the expression in different tumor subtypes as well as the relation to metastasis 
formation was determined. (B) Log2 fold change of DEGs (paired analysis of all cell lines, p < 0.01) comparing 
2D to 3D cell cultures versus log2 fold change comparing TNBC to ER positive primary tumors (left). Number 
of genes in each quadrant (right). (C) Log2 fold change of DEGs (paired analysis of basal A and basal B cells, 
p < 0.01) comparing 2D to 3D cell cultures versus log2 fold change comparing TNBC to ER positive breast 
tumors (left). Number of genes in each quadrant (right). (D) Density plot of DEGs (paired analysis of all, basal 
A and basal B cell lines respectively, p < 0.01) with a significant hazard ratio (HR). Blue = density plot for DEGs 
with increased expression in 2D cultures. Red = density plot for DEGs with increased expression in 3D cultures. 
Venn diagrams show the fraction of DEGs showing a significant HR. (E) Heatmap (Euclidean distance, complete 
linkage) of log2 fold change of CDK expression levels comparing 2D to 3D cultures (orange cluster is enlarged on 
the right) and log2 fold change of aurora kinase A and B comparing 2D to 3D cultures for different cell lines. (F) 
Hazard ratios and 95% confidence interval (CI) for CDKs higher expressed in 2D and aurora kinase A and B.
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Differential sensitivity of 3D TNBC cultures to clinical relevant kinase inhibitors. CDKs, aurora 
kinases and proteasomal inhibitors are critical candidate drugs some of which are already in clinical trials or 
application; these inhibitors have mainly been studied in 2D cell culture  systems39–42. The respective targets of 
these various inhibitors were significantly lower expressed in 3D cultures (Fig. 3E, Suppl. Fig. 4A), potentially 
leading to a change in sensitivity. Here, we tested whether BC cell line drug sensitivity is dependent on the dif-
ferential transcriptome driven by the 2D and 3D culturing conditions. 4 basal A and 4 basal B breast cancer cell 
lines were cultured in both culturing systems, treated with several CDK inhibitors with different CDK selectivity 
(dinaciclib, flavopiridol, milciclib or palbociclib, Suppl. Table 5), aurora kinase inhibitors (aurora Kinase Inhibi-
tor I or TAK-901), proteasome inhibitors (MG132 or bortezomib) or EGFR inhibitors (erlotinib and gefitinib), 
after which the effect on proliferation was quantified using image-based analysis (Fig. 4A). Although the growth 
rates differed for the eight TNBC cell lines, there were neither subtype specific proliferation differences in either 
2D or 3D cultures (Suppl. Fig. 5A-D) nor a correlation between growth rates in 2D and 3D cultures (Suppl. 
Fig. 5E). As expected by the decrease in expression of cell cycle related genes, all cell lines showed a significant 
decrease in growth rate in 3D cultures compared to 2D cultures (Suppl. Fig. 5F-G). Remarkably, this differential 
growth rate between 2 and 3D did not result in a significant change in sensitivity to anti-proliferative treatments 
such as CDK and aurora kinase inhibitors (Fig. 4B-C, Suppl. Figure 6A-C). The same was true for the protea-
some; although the expression of many proteasome factors was down-regulated in 3D, the sensitivity towards 
proteasome inhibitors MG132 and bortezomib did not change (Fig. 4B, Suppl. Figure 6D).
EGFR is higher expressed in TNBC compared to ER positive BC and is another important drug target in BC 
 treatment43–45. In contrast to CDKs, aurora kinases and proteasomal factors, EGFR was higher expressed in 3D 
for some basal cell lines (Suppl. Figure 7A). Therefore we predicted that these cells would be more sensitive to 
EGFR inhibitors such as erlotinib and gefitinib. The majority of the basal cell lines used in this study were resist-
ant to EGFR inhibitor treatment in 2D, except for MDA-MB-468 and a partial sensitivity seen with HCC1806 
(Fig. 4D,E). Interestingly, HCC1143, HCC1954 and SUM149PT cell lines became more sensitive to both erlo-
tinib and gefitinib in 3D cultures, while BT549, Hs578T and MDA-MB-231 remained resistant. This increased 
sensitivity was likely not directly related to EGFR RNA expression or its signaling pathway (Suppl. Figure 7A), 
since EGFR expression was also almost twice upregulated in the resistant MDA-MB-231 cell line. As shown 
before, basal cell lines in 3D cultures demonstrated differences in invasive behavior with a significantly higher 
invasion capacity for basal B (except for SUM149PT) compared to basal A cell lines (Fig. 2C, Suppl. Figure 7B-
C). Interestingly, only the invasive cell lines remained resistant to EGFR inhibitors in 3D cultures. This was not 
related to differences in 3D growth rate (Suppl. Figure 7D), EGFR expression (Suppl. Figure 7E-F), expression of 
genes involved in EGFR signaling (Suppl. Figure 7G-H) or mutations in the EGFR gene based on the COSMIC 
database (data not shown). A recent paper by Savage et al.observed heterogeneous EGFR expression in breast 
cancer patient-derived xenografts (PDX) and showed that the sensitivity to EGFR inhibitors such as gefitinib is 
determined by the variation rather than the mean EGFR expression; PDX models bearing heterogeneous expres-
sion of EGFR were more sensitive towards  gefitinib46. EGFR-high subpopulations were characterized by growth 
inhibition upon gefitinib treatment and enhanced expression of mesenchymal-stem cell  markers46. Interestingly, 
the same mesenchymal-stem cell markers were also more highly expressed in non-invasive EGFR-inhibitor sensi-
tive cells in both 2D (Fig. 4F) and 3D cultures. We hypothesize that when losing oncogenic proliferative signaling 
pathways in 3D conditions, these cell lines became more dependent on EGFR related stem cell-mesenchymal 
pathways and therefore more vulnerable to EGFR inhibitor treatment.
Altogether, we demonstrated that differential gene expression does not always relate to changes in drug 
sensitivity, especially in case of cell cycle related genes. Non-invasive cells were sensitive to EGFR inhibitors in 
3D systems irrespective of the EGFR expression levels, suggesting that other factors than single gene expression 
patterns might be involved in drug sensitivity.
Gene expression patterns of basal cell lines cultured in 3D are better correlated to human 
patient tumors than 2D cultured samples. For efficient drug development, it is vital to choose the opti-
mal in vitro test system in which the regulation of pathways correlates as close as possible to the human primary 
tumor situation. To compare the translational value of both 2D and 3D culture systems for human patient BC 
tumors, we calculated the correlation between cell line and patient RNA expression levels derived from TCGA 
(Fig. 5A). Correlations were calculated based on all genes and patients, but also focused on DEGs between 2 
and 3D culturing systems, specific pathways or specific patient tumor subtypes (Fig. 5A). Taking into considera-
tion all genes and all patient tumors, luminal cell lines in 2D culture were better correlated to patient tumors 
than basal cell lines in 2D culture (Fig. 5B). However, for the basal subtypes only, this correlation improved 
significantly for 3D cultures (Fig. 5B,C). The same trend was observed when only analyzing ER positive tumors 
both when taking into consideration all genes (Suppl. Figure 8A) and genes involved in the Reactome estrogen 
receptor-mediated signaling pathway (Suppl. Figure 8B). For TNBC, the correlation of basal and luminal cell 
lines was similar in 2D cultures, but much higher for basal (mainly basal A) cell lines in 3D cultures (Suppl. Fig-
ure 8C). Similarly, DEGs mainly contributed to increased correlations for the basal cell lines (Fig. 5D). Remark-
ably, the correlation of basal-specific DEGs showed a slightly larger increase in ER positive tumors compared 
to TNBC (Suppl. Figure 9 and Suppl. Figure 10) suggesting that the DEGs might have an important function in 
all patient tumors regardless of the subtype. Plotting the correlations of basal B subtype specific DEGs demon-
strated that the correlation increase in 3D could be attributed to a small subset of DEGs; these genes were not 
or low expressed in 2D, but show increased levels in 3D (Fig. 5E, red box). Gene set enrichment analysis on this 
subset of genes revealed that the majority of these DEGs is involved in extracellular matrix organization and 
collagen formation (Fig. 5F), suggesting that studying these pathways in 3D cultures might be more relevant 
for human patient tumors. Furthermore, assessment of Reactome pathway expression correlations between all 
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Figure 4.  Effect of DEG inhibitors on cell line proliferation in 2D and 3D. (A) Experimental setup. 4 basal 
A and 4 basal B cell lines were plated in 2D and 3D conditions, after which they were treated with 6 different 
concentrations of CDK, Aurora Kinase, Proteasome or EGFR inhibitors. 4 days after treatment, cells were fixed 
and proliferation was assessed. (B) Log IC50 (uM) for CDK inhibitors dinaciclib en flavopiridol and proteasome 
inhibitors bortezomib and MG132 in 2D and 3D cultures of basal A and basal B cell lines. (C) Dose response 
curves of dinaciclib en flavopiridol in 2D and 3D cultures of basal A and basal B cell lines. Mean + stdev for 
technical duplicates in 2D cultures. Mean + stdev for technical quadruplicates in 3D cultures. (D) Log IC50 of 
EGFR inhibitors erlotinib and gefitinib in basal A and basal B cell lines. (E) Dose–response curves of erlotinib 
and gefitinib in 2D and 3D cultures of basal A and basal B cell lines. Mean + stdev for technical duplicates in 2D 
cultures. Mean + stdev for technical quadruplicates in 3D cultures. (F) Heatmap (complete linkage, Euclidean 
distance) of log2 expression of mesenchymal-stem cell markers in basal A and basal B cell lines. Cell line color 
indicates 3D invasiveness; red = invasive, blue = non-invasive.
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Figure 5.  Comparison the transcriptomes of 2D and 3D cell culture models with patient derived primary 
tumor transcriptomes. (A) Analysis overview. Spearman correlations were calculated between the different 
transcriptomes using log2 normalized gene expression levels taking into consideration cell line subtypes, 
tumor subtypes and different gene sets. (B) Spearman correlation of log2 normalized RNA expression levels 
between cell lines and patient primary breast tumors (n = 1097). Boxes represent median and interquartile range 
of all tumor correlations. All genes and all tumors (irrespective of subtype) were included in the correlation 
calculations. (C) Difference in spearman correlation comparing 2D and 3D cell line cultures matched by patient 
tumor. All genes and all tumors were included in the correlation calculations. Boxes represent median and 
interquartile range of the difference in spearman correlation for all tumors. (D) Spearman correlation of log2 
normalized RNA expression levels of basal B DEGs (paired analysis, p < 0.01) between cell lines and patient 
primary breast tumors (n = 1097). Boxes represent median and interquartile range of all tumor correlations. 
Only DEGs comparing 2D and 3D cultures for the basal B cell lines were included in the correlation calculations 
(top). Difference in spearman correlation comparing 2D and 3D cell line cultures matched by patient tumor. 
Only DEGs comparing 2D and 3D cultures for the basal B cell lines were included in the correlation calculations 
(bottom). Boxes represent median and interquartile range of the difference in spearman correlation for all 
tumors. (E) Log2 normalized RNA expression levels of basal B DEGs comparing 2D to 3D cultures (paired 
analysis, p < 0.01) in basal B cell lines and TCGA patient primary breast tumors. Red squares: genes with log2 
RNA expression < 2. (F) Top 5 pathways of over-representation analysis of basal B DEGs comparing 2D to 3D 
cultures (paired analysis, p < 0.01) not or low expressed in 2D cultures and higher expressed in 3D cultures.
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human patient tumors and 2D and 3D models emphasized that the optimal model is highly dependent on the 
pathway of interest (Suppl. Figure 11A).
Discussion
Although there are increasing efforts to use 3D tumor cell cultures to evaluate the efficacy of candidate target 
therapies, a systematic comparison between the cellular physiology of 2D and 3D cultures is still lacking. Here 
we compared the transcriptome of BC cell lines cultured in 2D and 3D conditions to (1) uncover the differential 
pathway expression linked to subtype-specific morphological changes and (2) identify the most suitable model 
for future drug screens. Consistent with previous comparisons of 2D and 3D  cultures47, we demonstrate that 
BC cells in a 3D matrigel environment have a decreased expression of genes important in cell cycle pathways, 
including various CDKs and aurora kinases, regardless of the subtype. Of relevance, despite the downregulation 
of these gene sets in 3D, we did not observe a differential potency of CDK and aurora kinase inhibitors compar-
ing 2D and 3D cultures. Regardless of this lack of potency, the gene expression patterns of 3D cultures better 
resembled the BC patient transcriptome, in particular for TNBC subtypes.
We observed that cell lines of the basal A subtype showed a clear non-invasive spheroid morphology in 
3D. In contrast, cell lines of the basal B subtype demonstrated a distinct invasive phenotype; an exception for 
the basal B phenotype was the SUM149PT, that shows ambiguous classification and has also sometimes been 
classified as basal  A25,26,28. Also needs to be noted that the MDA-MB-231 cell line that was classified as basal B 
and has been used in this context in many studies, demonstrated to be a poor basal cell line representative in a 
recent  study48. These contrasting phenotypes between basal A and basal B cells are likely related to differences 
in expression of a small subset of extracellular matrix interacting and cell–cell adhesion genes. Thus, the basal 
B cells upregulated genes involved in collagen biosynthesis and breakdown of the extracellular matrix in 3D 
cultures, while these genes were downregulated in basal A cells. Moreover, the higher basal levels of E-cadherin 
in the basal A subtype could contribute to the less invasive phenotype observed in 3D cultures. The differences 
in cell line invasiveness and related pathway regulation for basal subtypes could be specific to the selected culture 
environment. Future studies using a 3D environment without the presence of an external extracellular matrix 
such as ultra-low attachment plates or spinner vessels would reveal the effects of the matrix composition on 
pathway regulation and cell phenotype.
CDKs, aurora kinases and proteasomal factors that were higher expressed in 2D, showed genuine higher 
expression levels in more aggressive breast tumors and cell lines, and were positively related to metastatic dis-
ease in breast cancer patients. Several aurora kinase inhibitors and Cell cycle-related CDK inhibitors have been 
developed of which some show promising results in clinical trials and are almost facing towards the  clinic33–36. 
Next, proteasomal inhibition could disrupt essential cellular pathways resulting in cancer cell death 37,38,49,50. To 
investigate whether transcriptomic differences change drug sensitivity and define the optimal in vitro model for 
future drug screening; we systematically treated cell lines in both 2D and 3D cultures with specific inhibitors 
against CDKs, aurora kinases and the proteasome. Whereas previous studies mainly identified reduced sensitivity 
towards established drugs (chemotherapeutics, endocrine agents and HER2-targeting agents) in 3D cultures in 
mostly HER2 positive cell  lines51–53, no change in sensitivity for CDKs, aurora kinases and proteasomal factors 
comparing 2D and 3D cultures was observed with our experimental setup. While the drugs that we tested were 
not evaluated in these studies, the discrepancies can also be explained by the differences in cell lines used and 
culture conditions. Additionally, we cannot exclude that limited differential sensitivity between 2 and 3D for the 
selected drug targets is related to limited changes of the target protein levels. For example, EGFR expression per 
se does not explain EGFR inhibitor sensitivity, and that EGFR inhibitors are effective in blocking EGFR auto-
phosphorylation, without impacting on downstream  signaling54. Hence, the TNBC proliferative and survival 
signaling wiring is complex and multiple pathways can contribute to overcome kinase inhibitor efficacy. Regard-
less, our data do indicate that across a broader panel of TNBC cell lines, typically 2D screening for the candidate 
drug targets will be as effective as 3D screening in identifying drug responses. To determine the optimal future 
screening model to assess efficacy of new targeted therapies, a thorough understanding of the overall clinical 
translation of the test system for specific cancer types, including TNBC, will be essential.
For basal BC cell lines the transcriptome of 3D cultures demonstrated increased similarity towards human 
patient tumor transcriptomes, which was mainly caused by elevated levels of genes involved in extracellular 
matrix interactions. On the contrary, the transcriptome profile of luminal cell lines was already highly comparable 
to the patient tumor transcriptome in 2D conditions, but did not improve in 3D settings. Importantly, similarity 
of transcript levels was highly pathway and subtype dependent. Next to the pathway of interest, the ideal in vitro 
model might change depending on the BC subtype of interest. In general, pathways in triple-negative patient 
tumors are better correlated to basal cell lines than the same pathways in ER-positive tumors.
Altogether, we can conclude that our systematic transcriptome analysis uncovered major differences between 
2 and 3D models thereby increasing the global understanding of these in vitro test systems. Defining ‘the best 
in vitro model’ with efficient clinical translation is yet difficult and dependent on both the pathway and subtype 
of interest, although in general 3D cultures correlated better to human patient tumors. To support such a selec-
tion, we established an in silico web tool in to allow (1) differential expression of genes between 2 and 3D BC 
cell lines, (2) collect gene expression levels in different breast cancer subtypes (cell lines as well as patient tumor 
data) and (3) calculate correlation between different cell lines/culture conditions with human patient tumors 
(https:// doi. org/ 10. 5281/ zenodo. 45602 97).
We performed a systematic transcriptomic comparison between 2 and 3D BC cell lines. Although clear 
transcriptomic differences were identified between 2 and 3D culturing systems, additional proteomic analysis 
would add a layer of information that could help to validate the transcriptomic findings and more intensively 
discriminate between the different models. In this study, we did not include other in vitro cell models that are of 
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relevance for BC anticancer therapy development, including BC tumor organoids, short-term patient-derived 
xenograft cell cultures, stem cell reprogramming and tumors-on-a-chip13,55–57. These models that are closer to 
the patient situation have higher costs and cannot yet be applied in similar throughput as 2D plastic models, 
but are recently widely exploited for their application in drug  screening58–61. Future systematic comparisons of 
the transcriptome and proteome of all these test systems in comparison with large BC patient transcriptome 
and proteome datasets, and their response to candidate drug targeted therapeutic approaches will be essential 
to provide clarity about the most optimal pre-clinical in vitro test systems.
Materials and methods
Cell culture. All cell lines were purchased from ATCC. Cells were grown in RPMI-1640 medium (Gibco, 
ThermoFisher Scientific, Breda, The Netherlands) supplemented with 10% FBS (GE Healthcare, Landsmeer, The 
Netherlands), 25 IU/ml penicillin and 25 µg/ml streptomycin (full RPMI) (ThermoFisher Scientific) at 37 °C in 
a humidified 5%  CO2 incubator. For 2D cultures, cells were grown on plastic tissue culture plates (Corning). For 
3D cultures, cells were grown in a gel-mixture containing 6 mg/ml matrigel (Corning, Lot# 5061003), 0.5 mg/ml 
collagen (Corning, Lot# 5092001), 3.7 g/L  NaHCO3 and 0.05 M HEPES.
RNA isolation. For 2D cultures, cells were plated in a 6-well tissue culture plate (Corning, 3516) in full 
RPMI. RNA was collected 2 days after plating at 70% confluency using RNeasy plus mini kit (Qiagen) according 
to the manufacturer’s protocol.
For 3D cultures, cells were plated in a 24-wells tissue culture plate (Corning, 3524). Wells were pre-coated 
with 200 μl matrigel (Corning, Lot# 5061003, 9.4 mg/ml) and cells were plated in a total volume of 400 μl. The 
following densities were used for the different cell lines: MDA-MB-231 (200 cells/μl), Hs578T (200 cells/μl), 
BT549 (200 cells/μl), SUM149PT (250 cells/μl), HCC1143 (250 cells/μl), HCC1806 (250 cells/μl), HCC1954 (250 
cells/μl) and MDA-MB-468 (250 cells/μl). After 30 min incubation at 37 °C, 1200 μl full RPMI was added. RNA 
was collected 7 days after plating using the QIAzol method to reduce matrigel pollution. RPMI was removed, 
1.2 ml QIAzol (Qiagen) was added per well and cells were lysed by repetitive pipetting. Cells were incubated for 
5 min at room temperature and 240 μl chloroform was added, followed by 2–3 min incubation at room tempera-
ture. Samples were centrifuged for 15 min at 4 °C (12,000 × g), the upper aqueous phase was collected and RNA 
was precipitated by mixing with 600 μl isopropanol. Samples were incubated for 10 min at room temperature, 
followed by 15 min centrifugation at 4 °C (12,000 × g) and washing with 1.2 ml 75% v/v ethanol. Samples were 
centrifuged for 5 min at 4 °C (7500 × g). Then the supernatant was removed and the pellet was air-dried and 
dissolved in 30 μl RNase free water.
RNA sequencing and analysis. DNA libraries were prepared with the TruSeq Stranded mRNA Library 
Prep Kit and sequenced according to the Illumina TruSeq v3 protocol on an Illumina HiSeq2500 sequencer. 
100 base pair paired-end reads were generated and alignment was performed using the HiSat2 aligner (version 
2.2.0.4) against the human GRCh38 reference genome. Gene expression was quantified using the HTseq-count 
software (version 0.6.1) based on the ENSEMBL gene annotation for GRCH38 (release 84). Count data was nor-
malized using the DESeq2  package62 and DEGs were selected based on log2 fold change > 1 or <  − 1. Paired t-test 
were performed on the normalized RNA-seq data using BRB-ArrayTools (v4.4.1) developed by Dr. Richard 
Simon and the BRB-ArrayTools Development Team and R (v3.2.2). Genes with p-value < 0.01 were considered 
significant. Upon acceptance, RNA sequencing data will be available in the Sequence Read Archive.
Drug screening. For 2D drug screening, cells were plated in a 96-well tissue culture plate (Corning, 3599) 
using the following cell densities: HCC1143 (8000 cells/well), HCC1806 (8,000 cells/well), HCC1954 (8000 cells/
well), MDA-MB-468 (10,000 cells/well), Hs578T (4,000 cells/well), MDA-MB-231 (5000 cells/well), SUM149PT 
(8000 cells/well) and BT549 (8,000 cells/well). Drug treatment was performed 16 h after plating and 4 days after 
treatment, cells were fixed for sulforhodamine B (SRB) colorimetric proliferation  assay63 previously described 
by our  group64.
For 3D drug screening, cells were plated in a 384-well µclear plate (Greiner, 781091) using a CyBi Selma 
96/60 robotic liquid dispenser (Analytik Jena AG, Jena, Germany). The same gel composition and cell densities 
were used as in the RNA isolation procedure. Cells were plated in a total volume of 14.5 μl matrigel-collagen 
mix. After 30 min incubation at 37 °C, 44.5 μl full RPMI was added. Drug treatment was performed 3 days after 
plating and 4 days after treatment, cells were fixed and stained in 0.05 µM Phalloidin Rhodamin (Sigma Aldrich), 
0.4 µg/ml Hoechst 33258 (Fisher Biotech), 0.1% Triton X-100 Triton (Sigma Aldrich) and 3.7% formaldehyde 
(Sigma Aldrich) in PBS O/N at 4 °C. Plates were washed with PBS and imaged using ImageXpress Micro XLS 
system (Molecular Devices, CA, USA).
Both in 2D and 3D cultures, cells were treated with 6 concentrations of the following inhibitors: MG132, 
bortezomib, flavopiridol HCl, dinaciclib, palbociclib, milciclib, aurora kinase inhibitor I, TAK-901, gefitinib and 
erlotinib (all Selleck Chem). DMSO was used as drug vehicle control.
Drug screen normalization and analysis. SRB absorbance values were used to analyze 2D cell line pro-
liferation. To analyze the 3D cultures the acquired image stacks (4 × objective, 40 sections per well, 50 µm step 
size) were processed in OcellO Ominer 3D image analysis platform. The software processes the DAPI channel 
to measure the number of nuclei and the shapes of the nuclei in each image stack and integrates this informa-
tion with the shape and number of tumor cell clusters detected in the TRITC channel. The software was used to 
process the total phalloidin area as measurement of proliferation.
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Proliferation was normalized to the absorbance (2D) or phalloidin area (3D) before treatment (set at 0%) 
and DMSO treatment (set at 100%). A nonlinear sigmoidal dose–response (with variable slope) curve was used 
to fit the data and retrieve the IC50 values using Graphpad Prism 7.00.
Immunofluorescence. For 2D immunofluorescence staining, cells were plated in a 96-well μclear plate 
(Greiner). Cells were fixed and permeabilized 72 h after plating by incubation with 1% formaldehyde and 0.1% 
Triton X-100 in PBS and blocked with 0.5% w/v BSA in PBS. Cells were incubated with 1:10,000 Hoechst 33258 
combined with 1:2000 rhodamine-phalloidin (Molecular Probes, R415) for 1 h at room temperature. Cells were 
imaged with a Nikon Eclipse Ti microscope and 20 × oil objective.
Hierarchical clustering and pathway analysis. Over-representation analysis was performed using 
Consensus  PathDB65 using KEGG and Reactome databases. Ranked gene set enrichment analysis (GSEA) was 
performed on the full ranked gene  lists66. T-sne plots were generated using the tsne R package. Hierarchical 
clusterings were generated using the pheatmap R package, based on complete linkage and Euclidean distance or 
correlations as described in the figure legend.
Data retrieval and normalization. Normalized total gene expression data from The Cancer Genome 
Atlas (TCGA) were obtained by using the TCGA Assembler R  package67 after the new release in January 2017. 
Normalized reads were log2 transformed before further analyses were performed. For calculating spearman 
correlations between the TCGA and cell line RNA sequencing data, log2 normalized data were used for both 
datasets. Microarray data of primary tumors of 867 untreated patients (MA-867 dataset) used to calculate hazard 
ratios was previously published and publicly available (GSE2034, GSE5327, GSE2990, GSE7390 and GSE11121). 
Raw .cel files were downloaded, processed with fRMA and batch effects were corrected using ComBat.
Ethical approval. This article does not contain any studies with human participants or animals performed 
by any of the authors.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request. Raw sequencing data will become publicly available upon publication and can 
currently be obtained by request.
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